ANI Pharmaceuticals Inc (NASDAQ:ANIP) Screens as High Growth Momentum Stock Meeting Minervini Trend Template

ANI Pharmaceuticals Inc (NASDAQ:ANIP) has recently appeared through a screening method that joins Mark Minervini's strict Trend Template with a High Growth Momentum (HGM) rating. This two-part method finds companies displaying both good technical price trends and solid fundamental growth features, a pairing Minervini supports for finding possible market leaders. The plan focuses on stocks in clear uptrends with quickening earnings and sales, holding that excellent technical condition frequently reflects basic fundamental health.

Meeting the Minervini Trend Template

The Minervini Trend Template is an organized technical structure made to find stocks in strong, continuing uptrends. ANI Pharmaceuticals meets the main technical requirements, which is the basic first stage in the SEPA (Specific Entry Point Analysis) method.

• Price Above Key Moving Averages: The stock's present price of $94.79 trades well above its increasing 50-day ($92.46), 150-day ($74.39), and 200-day ($70.37) simple moving averages. This arrangement confirms health across short, intermediate, and long-term periods.
• Moving Average Alignment: The 50-day moving average sits above both the 150-day and 200-day averages, while the 150-day is above the 200-day. This ordered positive arrangement, with all averages moving upward, shows organized and continuing buying interest.
• Position Relative to 52-Week Range: ANIP is trading 81% above its 52-week low of $52.50 and within 5% of its 52-week high of $99.50. Stocks close to their highs often have the speed to keep rising, a main idea of Minervini's focus on comparative performance.
• Superior Relative Strength: With a ChartMill Relative Strength rating of 92.32, ANIP is doing better than over 92% of the whole stock market. This outstanding comparative result is a central part of the plan, as market leaders usually show high relative strength before making their most important price gains.

Fundamentals Driving High Growth Momentum

Beyond a good chart, the Minervini plan looks for companies with quickening business basics. ANI Pharmaceuticals shows several qualities that make it suitable for high-growth investors, as seen in its good HGM rating.

• Explosive Earnings Growth: The company has shown notable earnings speed. The latest quarter showed EPS growth of 76% year-over-year, after earlier quarters of 40% and 63% growth. This sequence of quickening is just what the plan aims for, as "big earnings draw big notice" from institutional investors.
• Consistent Earnings Surprises: ANIP has exceeded EPS estimates in all of the last four quarters, with an average surprise of over 19%. These good surprises often cause analysts to change future estimates higher, creating a positive cycle of increasing expectations. In fact, the average EPS estimate for next year has been changed upward by 11% over the last three months.
• Solid Revenue Expansion: Top-line growth is also notable, with the last quarter showing sales growth of 53% year-over-year. The company has also exceeded revenue estimates for four straight quarters. Good and quickening revenue growth shows increasing market presence and demand for its products.
• Strong Cash Flow Generation: The company's free cash flow per share has increased by over 300% in the past year, reaching $5.63. High and increasing free cash flow gives financial room to put money into future growth, pay down debt, or give capital to shareholders.

Technical Health and Setup Assessment

According to the detailed ChartMill Technical Report, ANIP has a very good overall technical rating of 8 out of 10. The long-term trend is clearly positive, and the stock is a leading performer both in the wider market and within its pharmaceuticals industry. The report finds several main support areas, the most important being in the $87.45 to $92.46 range, which is made by a mix of trend lines and moving averages.

However, the report states that while the technical health is good, the present setup rating is lower because of recent changeable price movement within a wide one-month range. This indicates that while ANIP is a technically sound stock, investors may prefer to wait for a more clear period of stability or a move back toward support levels to find a good entry point with a positive risk/reward balance.

Discover More Potential Candidates

ANI Pharmaceuticals acts as a leading example of a stock that fits a controlled growth and speed plan. For investors looking to find similar chances, the predefined screen that found ANIP is a useful beginning point.

You can find more stocks that meet these joined technical and fundamental requirements by using the High Growth Momentum + Trend Template screen on ChartMill.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. The analysis is based on publicly available data and a specific screening methodology. All investments involve risk, and you should conduct your own research and consult with a qualified financial advisor before making any investment decisions.